Improving psychological treatments for obsessive-compulsive disorder
Enhancing the Acceptability of Psychological Treatments for Obsessive-compulsive Disorder
This study is testing whether a new type of therapy for obsessive-compulsive disorder is just as effective as the traditional method while being easier for patients to stick with.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Concordia University, Montreal Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Montréal, Quebec) |
| Trial ID | NCT03661905 on ClinicalTrials.gov |
What this trial studies
This study compares two psychological treatments for obsessive-compulsive disorder (OCD): the traditional Exposure and Response Prevention (ERP) and a newer cognitive therapy (CT) approach. The aim is to determine if the cognitive therapy is as effective as ERP while being more acceptable to patients, potentially reducing dropout rates. Participants diagnosed with OCD will be randomly assigned to either treatment group, and their symptoms and distress levels will be monitored throughout the study. The research seeks to enhance the acceptability of psychological interventions for OCD, which has historically faced high refusal and dropout rates.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with obsessive-compulsive disorder who can communicate in English.
Not a fit: Patients with psychosis, bipolar disorder, current suicidal ideation, or substance abuse issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more patients engaging with effective treatments for OCD, improving their overall mental health outcomes.
How similar studies have performed: Previous studies have shown that enhancing treatment acceptability can lead to better patient engagement, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of OCD * Ability to read, write, and communicate in English Exclusion Criteria: * Psychosis * Diagnosis of bipolar disorder (I or II) * Current suicidal ideation/intent * Current substance abuse * If participants are on medication they must be on a stable dose (i.e. have maintained a consistent dose for at least three months) and agree not to change their medication regimen for the duration of the study
Where this trial is running
Montréal, Quebec
- Concordia University — Montréal, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: Adam S Radomsky, PhD — Concordia University, Montreal
- Study coordinator: Stefanie L Lavoie, BA
- Email: stefanie.lavoie@concordia.ca
- Phone: 514-848-2424
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.